POTASSIUM CITRATE

Post-LOE

potassium citrate

Ascentage Pharma

ANDAORALTABLET, EXTENDED RELEASE

Approved

Feb 2021

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

POTASSIUM CITRATE (potassium citrate) by Ascentage Pharma is 12. Approved for renal tubular acidosis [see clinical studies (14, hypocitraturic calcium oxalate nephrolithiasis [see clinical studies (14, uric acid lithiasis with and 1 more indications. First approved in 2021.

Drug data last refreshed 1w ago

Mechanism of Action

12.1 Mechanism of Action When potassium citrate is given orally, the metabolism of absorbed citrate produces an alkaline load. The induced alkaline load in turn increases urinary pH and raises urinary citrate by augmenting citrate clearance without measurably altering ultrafilterable serum citrate.…

Worked on POTASSIUM CITRATE at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

POTASSIUM CITRATE

Mechanism of Action

Indications (1)

Clinical Trials (1)